Zevra Therapeutics, Inc. (ZVRA)Healthcare | Biotechnology | Boston, United States | NasdaqGS
13.18 USD
-0.17
(-1.273%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 13.24 +0.06 (0.480%) ⇧ (July 13, 2026, 7:59 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 3:04 a.m. EDT
The investment thesis here is a classic turnaround play on a biotech firm that has finally proven its commercial viability. While the stock has suffered a brutal multi-year decline, dropping roughly 81% from its peak, the fundamentals have flipped entirely in the last two years. Revenue exploded by 77.5%, and the company is now generating significant free cash flow with healthy margins. This shift from a cash-burn story to a profitable one is the primary catalyst for the long-term rating of 4.5 stars; the business quality is now exceptional relative to its depressed valuation, trading at a low P/E despite the recent surge. However, the short-term outlook remains cautious due to the heavy options positioning. The sheer volume of put buying at strikes like $5 and $8 suggests the market is still bracing for a sharp correction or is using these strikes as a hard floor. This creates a tension: the fundamentals scream 'buy,' but the speculative crowd is betting on a pullback. The statistical forecast model offers almost no guidance, reflecting the noise inherent in such volatile, small-cap biotech moves. For a patient investor, the current price represents a compelling entry point given the proven growth and cash generation, but the immediate path may be choppy as the market digests the recent rally. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.134572 |
| MSTL | 0.135230 |
| AutoARIMA | 0.138782 |
| AutoETS | 0.138786 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 33% |
| H-stat | 29.47 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.187 |
| Excess Kurtosis | -1.33 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.557 |
| Revenue per Share | 2.169 |
| Market Cap | 779,136,832 |
| Trailing P/E | 6.56 |
| Forward P/E | 11.03 |
| Beta | 0.85 |
| Profit Margins | 101.58% |
| Previous Name | KemPharm, Inc. |
| Website | https://www.zevra.com |
As of July 11, 2026, 3:04 a.m. EDT: Speculators are positioning aggressively for downside protection, evidenced by massive open interest in deep out-of-the-money puts (strikes 5.0 and 8.0) expiring late in 2026 and 2027, which dwarfs call volume at those strikes. Conversely, call activity is concentrated near the money and slightly out-of-the-money, suggesting a belief in a modest rebound or consolidation rather than a massive breakout. The skew indicates a 'bear put' strategy where traders are hedging against a potential drop while maintaining a neutral-to-slightly-bullish bias for a recovery.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.04378426 |
| Address1 | 101 Federal Street |
| Address2 | Suite 103 |
| All Time High | 418.4 |
| All Time Low | 1.936 |
| Ask | 16.69 |
| Ask Size | 1 |
| Audit Risk | 8 |
| Average Daily Volume10 Day | 1,785,080 |
| Average Daily Volume3 Month | 1,683,665 |
| Average Volume | 1,683,665 |
| Average Volume10Days | 1,785,080 |
| Beta | 0.852 |
| Bid | 9.46 |
| Bid Size | 1 |
| Board Risk | 7 |
| Book Value | 3.481 |
| City | Boston |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 13.18 |
| Current Ratio | 4.89 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 13.29 |
| Day Low | 13.01 |
| Debt To Equity | 0.557 |
| Display Name | Zevra Therapeutics |
| Dividend Date | 1,609,113,600 |
| Earnings Call Timestamp End | 1,778,099,400 |
| Earnings Call Timestamp Start | 1,778,099,400 |
| Earnings Timestamp | 1,778,097,600 |
| Earnings Timestamp End | 1,778,097,600 |
| Earnings Timestamp Start | 1,778,097,600 |
| Ebitda | 12,734,000 |
| Ebitda Margins | 0.10413 |
| Enterprise To Ebitda | 45.521 |
| Enterprise To Revenue | 4.74 |
| Enterprise Value | 579,667,776 |
| Eps Current Year | 1.22333 |
| Eps Forward | 1.195 |
| Eps Trailing Twelve Months | 2.01 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 11.96 |
| Fifty Day Average Change | 1.2200003 |
| Fifty Day Average Change Percent | 0.10200671 |
| Fifty Two Week Change Percent | 4.378426 |
| Fifty Two Week High | 15.035 |
| Fifty Two Week High Change | -1.8549995 |
| Fifty Two Week High Change Percent | -0.12337875 |
| Fifty Two Week Low | 7.16 |
| Fifty Two Week Low Change | 6.0200005 |
| Fifty Two Week Low Change Percent | 0.8407822 |
| Fifty Two Week Range | 7.16 - 15.035 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,429,191,000,000 |
| Float Shares | 54,926,189 |
| Forward Eps | 1.195 |
| Forward P E | 11.029288 |
| Free Cashflow | 25,852,250 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 61 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.86070997 |
| Gross Profits | 105,255,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01282 |
| Held Percent Institutions | 0.725 |
| Implied Shares Outstanding | 59,115,084 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,609,113,600 |
| Last Split Factor | 1:16 |
| Long Business Summary | Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial to treat narcolepsy. The company is developing Celiprolol, an investigational product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit and hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and MIPLYFFA for the treatment of niemann-pick disease type C, an ultra-rare neurodegenerative disease. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. The company was incorporated in 2006 and is headquartered in Boston, Massachusetts. |
| Long Name | Zevra Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 779,136,832 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_65059726 |
| Most Recent Quarter | 1,774,915,200 |
| Name Change Date | 2,026-07-13 |
| Net Income To Common | 117,001,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 788,299,645 |
| Number Of Analyst Opinions | 9 |
| Open | 13.2 |
| Operating Cashflow | 12,766,000 |
| Operating Margins | 0.24384001 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Peg Ratio | 10.67 |
| Phone | 888 958 1253 |
| Post Market Change | 0.0632 |
| Post Market Change Percent | 0.4795144 |
| Post Market Price | 13.2432 |
| Post Market Time | 1,783,987,195 |
| Prev Name | KemPharm, Inc. |
| Previous Close | 13.35 |
| Price Eps Current Year | 10.773871 |
| Price Hint | 2 |
| Price To Book | 3.7862685 |
| Price To Sales Trailing12 Months | 6.371275 |
| Profit Margins | 1.0157701 |
| Quick Ratio | 4.736 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.17 |
| Regular Market Change Percent | -1.27341 |
| Regular Market Day High | 13.29 |
| Regular Market Day Low | 13.01 |
| Regular Market Day Range | 13.01 - 13.29 |
| Regular Market Open | 13.2 |
| Regular Market Previous Close | 13.35 |
| Regular Market Price | 13.18 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 843,504 |
| Return On Assets | 0.027590001 |
| Return On Equity | 1.00652 |
| Revenue Growth | 0.775 |
| Revenue Per Share | 2.169 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 59,115,084 |
| Shares Percent Shares Out | 0.109799996 |
| Shares Short | 6,490,132 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 5,964,448 |
| Short Name | Zevra Therapeutics, Inc. |
| Short Percent Of Float | 0.111099996 |
| Short Ratio | 3.32 |
| Source Interval | 15 |
| State | MA |
| Symbol | ZVRA |
| Target High Price | 35.0 |
| Target Low Price | 21.0 |
| Target Mean Price | 27.88889 |
| Target Median Price | 27.0 |
| Total Cash | 200,616,000 |
| Total Cash Per Share | 3.394 |
| Total Debt | 1,147,000 |
| Total Revenue | 122,289,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 2.01 |
| Trailing P E | 6.5572143 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 9.98985 |
| Two Hundred Day Average Change | 3.1901503 |
| Two Hundred Day Average Change Percent | 0.31933916 |
| Type Disp | Equity |
| Volume | 843,504 |
| Website | https://www.zevra.com |
| Zip | 2,110 |